Inspira Technologies Oxy B.H.N Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Inspira Technologies Oxy B.H.N şirketinin toplam hissedar öz sermayesi $5.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $9.3M ve $3.6M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$7.36m
Eşitlik	US$5.74m
Toplam yükümlülükler	US$3.57m
Toplam varlıklar	US$9.31m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Inspira Technologies reports 1H results

Aug 11

Inspira stock soars 71% on developing non-invasive optical blood sensor Hyla

Jul 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IINN 'nin kısa vadeli varlıkları ( $7.8M ) kısa vadeli yükümlülüklerini ( $3.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: IINN şirketinin kısa vadeli varlıkları ( $7.8M ) uzun vadeli yükümlülüklerini ( $588.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IINN borçsuzdur.

Borcun Azaltılması: IINN un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: IINN şirketinin mevcut serbest nakit akışına dayanarak yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Tahmini Nakit Akışı: IINN tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Inspira Technologies Oxy B.H.N Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 30, 2024

New minor risk - Financial data availability

Inspira Technologies Oxy B.H.N. Ltd. Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism

Inspira Secures Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System

Independent Chairman of the Board notifies of intention to sell stock

Inspira Technologies OXY B.H.N. Ltd. Announces FDA Listing and Market Readiness of New Product

Inspira Technologies OXY B.H.N. Introduces the INSPIRA Cardi-ART, Aiming to Provide Oxygen to the Brain During Cardiac Arrest

New major risk - Shareholder dilution

Inspira Technologies OXY B.H.N. Ltd. Receives Israeli Regulatory Approval for the INSPIRA ART100 System

Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

Inspira™ Announces Start of Production of the Inspira™ Art100

Price target increased by 44% to US$13.00

Inspira™? and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth Causes Bloodstream Infections

Inspira™ Technologies Oxy B.H.N. Ltd. Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Inspira Technologies OXY B.H.N. Ltd. Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets

Inspira Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator

Inspira Technologies OXY B.H.N. Ltd. Introduces High-End Platform for Bio-Mimicking Blood parameters for Development and Testing of Core Technologies

Inspiratm Technologies OXY B.H.N. Ltd. Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System

New minor risk - Share price stability

Inspira Technologies Oxy B.H.N. Ltd. Announces Plans to Launch and Target Single-Use Disposable Blood Oxygenation Kit for A New Disposable Perfusion Market Opportunity

Inspira Technologies Oxy B.H.N. Ltd. has completed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies Oxy B.H.N. Ltd. has filed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies Oxy B.H.N. Ltd. has filed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies OXY BHN Ltd. Announces 95% Accuracy Results for HYLA™? Blood Sensor, Planning FDA Submission for Clearance in 2024

Inspira Technologies Oxy B.H.N. Ltd. Announces Appointment of Dan Gorfil to its Medical Advisory Board

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 27, 2023

Inspira Technologies Oxy B.H.N. Ltd. Announces Israeli Innovation Authority Grant for New VORTX Disposable Blood Oxygenation Technology

Inspira Technologies OXY BHN Ltd. Announces the Grant of an Additional Patent by the U.S. Patent and Trademark Office for its Respiratory Medical Device, the INSPIRAART500

Inspira Technologies Unveils the Inspira™ Art Line of Medical Devices At the World's Largest Extracorporeal Life Support Conference

Inspira™? Announces 510(k) FDA Submission of INSPIRA™? ART100 Towards Commercialization

Inspira Technologies Appoints Dr. Nir as Chief Medical Officer

Inspira Technologies Oxy B.H.N. Ltd. to Reveal the New ALICE Device at the World's Largest Extracorporeal Life Support Conference

Inspira™ Technologies OXY B.H.N. Ltd. Develops the VORTX™ Blood Oxygenator, a Unique Technology for Saturating Blood With Oxygen and Removing Carbon Dioxide

Inspira(TM) Technologies Receives Approval from Sheba Medical Center to Conduct Clinical Study of the HYLA(TM) Blood Sensor

Inspira Technologies Receives Patent by U.S. Patent Office for the INSPIRA ART System's Convertible Dual Lumen Cannula Device and Method of Use

Inspira Technologies Oxy B.H.N. Ltd. Begins Manufacturing of the ALICE™ CPB Device, ahead of planned 2023 FDA submission

Less than half of directors are independent

Inspira Technologies Oxy B.H.N. Ltd. Receives Patent by the Israeli Patent Office for Key Safety Component for the INSPIRATM ART System

Chairman of the Board notifies of intention to sell stock

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Oct 18, 2022

Inspira™ Technologies Performed HYLA™ Blood Sensor In-Vivo Study, in Preparation of Planned Human Studies

Inspira Technologies Oxy B.H.N. Ltd. Announces Changes in Management

Inspira Technologies reports 1H results

Inspira™ Technologies Reveals Next Generation Liby™ ECMO

Inspira Technologies Develops A Non-Invasive Blood Sensor

Inspira stock soars 71% on developing non-invasive optical blood sensor Hyla

Chairman of the Board notifies of intention to sell stock

Less than half of directors are independent

Inspira Technologies Appoints Daniella Yeheskely-Hayon as the New Chief Technology Officer

Inspira Technologies Oxy B.H.N. Ltd. Lists a Component of its ART and ECLS Systems on the U.S. Food and Drug Administration Class I 510(K) Exempt List

Inspira Technologies Oxy B.H.N. Ltd. Files A Pct Patent Application for Its Flagship Art Device and Proprietary Method of Use to Minimize the Need for Mechanical Ventilation

Inspira Technologies Oxy B.H.N. Ltd. has completed an IPO in the amount of $16.029091 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin